Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EIK 1001

Next Previous
X
Search
Drug Profile

EIK 1001

Alternative Names: BDB-001; EIK-1001

Latest Information Update: 29 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Birdie Biopharmaceuticals
  • Developer Birdie Biopharmaceuticals; Eikon Therapeutics; National Cancer Institute (France); Roche; Seven and Eight Biopharmaceuticals
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 21 Nov 2024 Eikon Therapeutics plans a phase II/III trial for Malignant melanoma (Metastatic disease, Late-stage disease, Combination therapy, First-line therapy) in November 2024 (NCT06697301)
  • 28 May 2024 Phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) is ongoing in USA (IV, Infusion) (NCT03486301)
  • 28 May 2024 Updated efficacy, adverse event and pharmacokinetics data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top